Unknown

Dataset Information

0

Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.

ABSTRACT:

SUBMITTER: Horby P 

PROVIDER: S-EPMC8298006 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Tocilizumab for severe COVID-19 pneumonia - Authors' reply.
| S-EPMC7431126 | biostudies-literature
Unknown Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply.
| S-EPMC7498220 | biostudies-literature
Unknown Authors' reply: Hypoalbuminemia in COVID-19.
| S-EPMC8662292 | biostudies-literature
Unknown Cancer and COVID-19 - Authors' reply.
| S-EPMC7544437 | biostudies-literature
Unknown COVID-19 in pregnant women - Authors' reply.
| S-EPMC7195406 | biostudies-literature
Unknown Mavrilimumab for severe COVID-19 - Authors' reply.
| S-EPMC7837188 | biostudies-literature
Unknown Tocilizumab in COVID-19 therapy: who benefits, and how?
| S-EPMC8298010 | biostudies-literature
Unknown Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.
| S-EPMC7834467 | biostudies-literature
Unknown Multiomics single timepoint measurements to predict severe COVID-19 - Authors' reply.
| S-EPMC9876580 | biostudies-literature
Unknown Widespread smell testing for COVID-19 has limited application - Authors' reply.
| S-EPMC7832202 | biostudies-literature